Ganguli Amitava, Walker Lauren, FitzGerald Richard Joaquim, Pirmohamed Munir
Department of Clinical Pharmacology and Therapeutics, Royal Liverpool University Hospital, Liverpool, UK. aganguli05@ yahoo.co.uk
Ann Pharmacother. 2009 Sep;43(9):1528-31. doi: 10.1345/aph.1L542. Epub 2009 Aug 18.
To report a case of spontaneous hemothorax following anticoagulation with low-molecular-weight heparin (LMWH) for the management of suspected pulmonary embolism.
A 66-year-old man with a background history of breast carcinoma was admitted with pleuritic chest pain. He was initially managed as a suspected case of pulmonary embolism. Dalteparin, an LMWH, was started at a maximum dose of 18,000 units subcutaneously once daily, according to British national prescribing guidelines. On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood. CTPA identified no pulmonary embolus or vascular abnormalities. Reaccumulation of hemothorax occurred over the 48 hours following drain removal, necessitating insertion of a second drain, which removed 1400 mL of blood-stained fluid. The patient's hemoglobin decreased from 12.7 to 8.5 g/dL and he received a 3-unit blood transfusion. Histologic assessment of pleural fluid revealed no malignancy and results of video-assisted thoracoscopic surgery were normal. Discontinuation of dalteparin on day 4 led to resolution of symptoms.
The causal association between anticoagulant therapy and spontaneous hemothorax remains relatively uncommon. The striking temporal relationship between commencing dalteparin on day 1 and subsequent development of effusion on day 4, following 3 doses of LMWH, led us to believe that the bleed occurred as a result of the therapy. Exclusion of other causes strengthened this conclusion. Application of the Naranjo probability scale categorized this adverse reaction as being probably due to LMWH.
Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.
报告1例在使用低分子肝素(LMWH)抗凝治疗疑似肺栓塞过程中发生自发性血胸的病例。
一名66岁有乳腺癌病史的男性因胸膜炎性胸痛入院。他最初被作为疑似肺栓塞病例进行处理。根据英国国家处方指南,开始皮下注射达肝素(一种LMWH),最大剂量为每日1次,每次18,000单位。在第4天,即注射3剂达肝素后,患者出现急性呼吸窘迫,计算机断层扫描肺动脉造影(CTPA)证实为大量右侧血胸,肋间引流出血1500 mL鲜血。CTPA未发现肺栓塞或血管异常。拔除引流管后的48小时内血胸再次积聚,需要插入第二根引流管,引出1400 mL血性液体。患者的血红蛋白从12.7 g/dL降至8.5 g/dL,他接受了3单位的输血。胸腔积液的组织学评估未发现恶性肿瘤,电视辅助胸腔镜手术结果正常。在第4天停用达肝素后症状得到缓解。
抗凝治疗与自发性血胸之间的因果关联仍然相对不常见。在第1天开始使用达肝素与第4天在3剂LMWH后出现积液之间明显的时间关系,使我们认为出血是该治疗的结果。排除其他原因强化了这一结论。应用Naranjo概率量表将这种不良反应归类为可能是由于LMWH所致。
自发性血胸是与LMWH相关的一种罕见现象,但在开始使用LMWH后出现急性呼吸窘迫的病例中应予以考虑。